Home

Mohn Cancer Research Laboratory

Main content

Helse Bergen - Kreft

Mohn Cancer Research Laboratory (MCRL) was established in 2009 at the Laboratory Building at Haukeland University Hospital campus by Bergen Medical Research Foundation (BMFS) and Trond Mohn

The main focus of our research is to identify the genetic and molecular mechanisms that influence the risk of various types of cancer, as well as the mechanisms that have impact on treatment results of cancer patients.

Personalized cancer therapy
Aas og Eikesdal

Promising results for hormone therapy

Through the Petremac study, doctors at Haukeland have found that patients with hormone-sensitive breast cancer have a good effect, fewer side effects and need less invasive surgery when they receive hormone treatment instead of chemotherapy.

MEDPAGE TODAY
Screenprint Medpage Today 12/14/21

Annals of Oncology

Research on PARP inhibitors carried out at Mohn Cancer Research Laboratory and KG Jebsen's center for genome-directed cancer therapy receives attention in the international press after publication in the Annals of Oncology.

Therapy abroad
Skjermdump NRK TV

Hoping for a Cure

In the Norwegian tv-series "Håpets marked" (The Market of Hope",) host Lisa Tønne follows Norwegians who seek various types of medical treatment abroad.

Therapy abroad
Print screen BT

No miracles guaranteed

Bergens Tidende shares the story of Elisabeth Thomassen, who receives support from the am-car community to raise money to try treatment in the USA.

Study using PARP-inhibitors
Articel print screen Bergens Tidende

Targeted therapy

Bergens Tidende shares the story of Aud and Kristel on 5 November; two ladies who have both been treated for breast cancer.

Researchers at the laboratory work with the following issues:

   ● Somatic mutations that make cancer cells resistant to treatment.

   ● Germline factors that influence the risk of cancer and result in different clinical expressions and different degrees of side effects during treatment.

   ● Hormones and their role in cancer development and treatment of various hormone-sensitive cancers.

Research is mainly focused on cancer arising in the breast, ovaries, testes, prostate and the gastrointestinal tract as well as on malignant melanomas.

Mohn Cancer Research Laboratory is a modern facility, fully equipped with state of the art technology for translational cancer research, including an in-house massive parallel sequencing facility, cell culture facilities and infrastructure for all types of molecular analyses.

MCRL has scalable, dedicated servers and storage domains directly linked to our in-house sequencing infrastructure, within the frameworks of the IT-departments at the University of Bergen and Haukeland University Hospital.

 

 

Collaborations:

Norwegian Cancer Genomics Consortium

Molecular Genetics Group

Cancer Genome Project ved Wellcome Trust Sanger Institute

 

 

We are located at the Laboratory Building, floor 1M, Haukeland University Hospital campus.